Boothbay Fund Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Boothbay Fund Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-27,457	Closed	-$84K	–	2738
2022 Q2	$84K	Sell	27,457 -6,315	-19%	-$38.6K	﹤0.01%	2012
2022 Q1	$244K	Sell	33,772 -10,425	-24%	-$103K	0.01%	1763
2021 Q4	$724K	Buy	44,197 +29,197	+195%	+$340K	0.02%	881
2021 Q3	$149K	Hold	15,000	–	–	﹤0.01%	1687
2021 Q2	$150K	Buy	+15,000	New	+$151K	﹤0.01%	1627

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Boothbay Fund Management's PRDS Position: Q3 2022 in Review

Boothbay Fund Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2022, closing a stake of 27,457 shares — an estimated $84K sold.

Boothbay Fund Management first reported a position in PRDS in Q2 2021 and held it in 5 quarters. The position peaked at $724K in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

Boothbay Fund Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Boothbay Fund Management sold 27,457 Pardes Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $84K.
Boothbay Fund Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Boothbay Fund Management's Pardes Biosciences, Inc. Common Stock position peaked at $724K in Q4 2021.
68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.